Led · Convertible Note · Jun 2024

SciTech Development is a clinical-stage pharmaceutical company focused on advancing next-generation cancer therapeutics via its proprietary nanotechnology drug-delivery platform. Its lead candidate, ST-001 nanoFenretinide, is in clinical trials for T-cell Non-Hodgkin Lymphoma across nine cancer centers and has produced a 100% disease control rate at the highest tested dose levels, including confirmed partial responses. Interim data suggest efficacy in both early- and late-stage patients, minimal side effects, and confirmed safety, encouraging participants to remain in the study. The company intends to extend clinical development of ST-001 into Small Cell Lung Cancer and explore additional oncology indications. Investor enthusiasm has been fueled by these results, enabling continued trial progress and pipeline expansion. SciTech has not reported commercial revenue, relying instead on successive convertible note financings to fund operations.